EPO and anemia: In the current study, the prevalence of anemia was >90% in patients with stage 5 CKD; this may be attributed to the decreased production of endogenous EPO due to a decrease in eGFR, as well as metabolic disturbances such as uremic toxins and electrolyte and acid-base imbalances.